

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

## Strategic Trading Analysis

Based on the detailed technical and fundamental report provided (generated date: 2026-02-14), here is the analysis for a positional trade in **TORNTPHARM.NS**.

### Step 1: Audit the Data

#### ● Data Present:

- **Price Structure:** Daily and Weekly candlestick charts with EMA overlays (20, 50, 200).
- **Trend Indicators:** Supertrend, MACD, Moving Averages.
- **Momentum/Volatility:** RSI, Bollinger Bands, Volatility Squeeze analysis.
- **Volume Analysis:** Volume bars, Moving averages, and distribution day counts.
- **Fundamental Snapshot:** Revenue/Net Income trends, RS Score, and Analyst estimates.

#### ● Data Missing:

- Specific Intraday Volume Profile (though general volume is present).
- Sector-wide heatmaps (though comparison to <sup>^CNXPHARMA</sup> is provided).

#### ● Confidence Level: High.

The report provides a comprehensive multi-timeframe technical view (Weekly/Daily/15min) alongside fundamental context, allowing for a precise technical assessment.

### Step 2: Analyze the Setup

#### ● Trend & Structure:

- **Primary Trend:** Strongly **Bullish**. The stock is trading above all key EMAs (20 > 50 > 200) on the daily chart (Page 6). The weekly chart (Page 23) shows a classic long-term uptrend riding the 20-week EMA.
- **Price Action:** The stock is currently consolidating near All-Time Highs (~INR 4,100 - INR 4,150). The "Seller Control" status (Page 20) and recent upper wicks on candles (Page 21) indicate short-term supply absorption at these levels.

#### ● Momentum & Strength:

- **MACD:** **Bullish**. The MACD line (38.71) is above the Signal line (34.75), and momentum is classified as "Strengthening" (Page 12).
- **RSI:** Neutral-**Bullish** at 59.33 (Page 16). It has room to run before hitting overbought territory (70+).
- **Relative Strength:** Concerning. The RS Score is 54.8/100, and the classification is "Weakening Leader" (Page 4). The stock is currently lagging the Pharma index (<sup>^CNXPHARMA</sup>) in the short term.

#### ● Volatility & Volume:

- **Bollinger Bands:** The bands are relatively tight (Bandwidth 0.05), suggesting a potential volatility expansion (squeeze) is imminent. The price is hugging the Upper Band (INR 4,108).
- **Volume:** Several "Distribution Days" were noted in Jan/Feb 2026 (Page 18). This suggests institutional selling into strength, which mandates caution.

**Confluence:** The long-term trend is up, but the immediate short-term action is choppy with signs of distribution. The stock is at a "make or break" resistance level. A breakout leads to a new leg up; a failure here leads to a test of the 50 EMA.

### Step 3: Formulate the Recommendation

Should I enter this stock now? NO.

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

**Reasoning:** While the long-term trend is pristine, the immediate setup shows "Seller Control" and lagging Relative Strength at resistance. Entering at current market price (CMP INR 4078) offers a poor Risk:Reward ratio as you are buying directly into overhead supply with signs of distribution. You should wait for the buyers to prove they have absorbed the supply by pushing the price above the recent consolidation range.

## Conditional Plan (Breakout Strategy):

- **Condition to Buy: Daily Close above INR 4,150.**
  - *Why:* This level clears the Upper Bollinger Band (INR 4,108) and the recent swing high wicks seen on the daily chart. This confirms the resumption of the uptrend and invalidates the recent "Seller Control" signal.
- **Entry Price: INR 4,150 - INR 4,160** (On the retest or immediate breakout).
- **Stop Loss: INR 3,900** (Closing Basis).
  - *Why:* This is just below the 50-day EMA (INR 3,923) and the lower Bollinger Band (INR 3,903). If it breaches this, the intermediate trend is broken.
- **Take Profit: INR 4,550 - INR 4,600.**
  - *Why:* This targets a 10-12% extension from the breakout point, typical for a renewed momentum move in a large-cap stock.

**Risk/Reward Ratio:** Approximately 1:1.8 (Risking ~6% to make ~11%).

*Note: If the stock fails to break INR 4,150 and drops, a secondary entry can be looked at near the INR 3,920 level (50 EMA support) if bullish reversal candles appear.*

## Candlestick Classification Analysis

Based on the **Candlestick Classification Analysis** found on [Page 20 \(Summary\)](#) and [Page 21 \(Chart\)](#) of the report, here is my professional assessment of the price action for **TORNTPHARM.NS**.

### Executive Summary: Immediate **Bearish** Pressure

The immediate price action suggests a **short-term bearish correction** is underway. The stock has shifted from an uptrend into a consolidation/pullback phase, with sellers currently seizing control of the daily timeframe.

### 1. Current Candle Signal: Seller Control (-1)

- **Classification:** The latest candlestick is classified as **Seller Control**.
- **Algorithmic Interpretation:** According to the provided logic, a (-1) score indicates a **moderate bearish candle**. It signifies that the price likely closed lower than it opened, potentially with a body size between 0.8-1.5 ATR, or a larger drop on lower volume.
- **Price Action Implication:** Sellers were able to push the price down by the close. While it wasn't a "Strong Seller Control" (-2) event (which would imply high volume panic selling), it indicates that buyers failed to defend the higher levels, and profit-taking is active.

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

## 2. Trend Conviction: Weakening Momentum

- **10-Day Trend Score (0.20):** This metric is critical. The scale ranges from -2 (Strong Bear) to +2 (Strong Bull). A score of **0.20** is barely positive.
- **Interpretation:** This low positive score indicates **indecision and exhaustion**. Over the last two weeks, the net result of buying vs. selling pressure has nearly equalized. The bulls have lost the strong momentum that drove the stock up previously. When a trend score collapses toward zero near a high, it is a classic sign of a **local top formation**.

## 3. Market "Personality" (Distribution Analysis)

Looking at the historical distribution of candles on Page 20:  
\* **No Control (0):** 123 occurrences (Dominant).

\* **Buyer Control (+1):** 61 occurrences.  
\* **Seller Control (-1):** 40 occurrences.  
\* **Strong Signals (+/- 2):** Extremely rare (Only 4 total).

**Trader's Insight:** This stock is a "**Grinder**." It does not typically make explosive moves (very few Strong Control candles). It spends most of its time in "No Control" (indecision) or mild "Buyer Control." Therefore, the current shift to "Seller Control" is significant because it deviates from the standard bullish drift.

## 4. Chart Analysis (Page 21)

- **Visual Structure:** The stock had a strong run-up peaking in early 2026 (right side of chart).
- **Recent Pattern:** We see a cluster of grey (No Control) and red (Seller Control) candles at the top. This represents **distribution**. The wicks on the upper side of recent candles suggest that every time price attempts to push higher, it is met with supply (selling).
- **Volume:** The volume on the recent decline appears moderate. It is not a crash, but rather a lack of buying interest at these elevated prices (approx INR 4078).

## Prediction: Which side should the future price be?

**Short-Term Direction: DOWN (Bearish)** I anticipate further downside or sideways consolidation in the immediate future (next 1-5 sessions).

- **Rationale:** The transition from "Buyer Control" to "Seller Control" combined with a collapsing 10-day Trend Score suggests the path of least resistance is lower. The bulls are exhausted.
- **The Setup:** The market is likely looking for a support level to reset. Since "Strong Seller Control" is rare, do not expect a crash, but rather a slow bleed or pullback to the 20-day or 50-day moving average (seen on Page 23 around the 3920-4000 zones).

**Trading Strategy:** \* **Aggressive:** Short positions could be taken on a break of the current candle's low, targeting the mean reversion (EMA 20/50). \* **Conservative:** Wait. Do not buy this dip yet. Wait for a "No Control" candle followed by a "Buyer Control" candle to confirm the pullback has ended. Currently, the knife is falling.

## News & Analyst Targets

Based on the latest search results as of February 14, 2026, here is the research report for Torrent

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Pharmaceuticals (TORNTPHARM).

## 1) Latest News for TORNTPHARM (Week of Feb 9 - Feb 14, 2026)

The most significant event this week was the announcement of Q3 FY26 financial results and a major corporate action.

- **Strong Q3 FY26 Earnings:** On February 13, 2026, Torrent Pharma reported robust quarterly numbers:
  - **Net Profit:** Jumped **26.2% YoY** to **INR 635 crore** (vs INR 503 crore last year).
  - **Revenue:** Rose **17.7% YoY** to **INR 3,303 crore**.
  - **EBITDA:** Increased **19% YoY** to **INR 1,088 crore**, with margins steady at **33%**.
  - **Growth Drivers:** The India business grew 14%, while Brazil (+27%) and US (+19%) markets showed strong double-digit growth.
- **Interim Dividend Declared:** The board declared a substantial interim dividend of **INR 29 per share** (580% on face value of INR 5).
  - **Record Date:** Fixed as **February 19, 2026**.
  - **Payment Date:** Expected on or around **March 6, 2026**.
- **Acquisition Completion:** The company successfully completed the acquisition of a controlling stake (approx. 48.8%) in **JB Chemicals & Pharmaceuticals**, consolidating it into its financials starting January 2026.
- **Regulatory Win:** Earlier in the quarter (Jan 2026), the company's **Dahej facility** successfully passed a USFDA inspection with **zero observations**, a key positive for its export business.

## 2) Brokerage Upgrades & Downgrades

Recent analyst activity has been largely positive or neutral, reflecting confidence in the company's branded generic strategy and recent acquisitions.

- **Jefferies:** Maintained a **BUY** rating in early January 2026, citing strong earnings visibility and sector tailwinds.
- **MarketsMojo:** Upgraded the stock from **Hold to BUY** in late December 2025, citing improved financial scores and technical bullishness.
- **Motilal Oswal:** Has maintained a **Neutral** stance in recent months, acknowledging strong franchise value but citing rich valuations.
- **Trendlyne Consensus:** The overall consensus from 7 tracked analysts is a **BUY**, though the average target price suggests limited immediate upside from the current market price of ~INR 4,080, indicating the good news may be priced in.

## 3) Other News Impacting TORNTPHARM

- **Sector-Wide Tariff Fears:** Like other export-oriented pharma stocks, Torrent Pharma saw some volatility earlier in the week due to fears of potential new US import tariffs. However, its strong domestic focus (India) acts as a hedge against this risk compared to peers.
- **Integration Synergies:** The market is closely watching the integration of **JB Chemicals**. Management expects cost synergies of **INR 400-450 crore** over the next 2-3 years, which is a key indirect driver for future margin expansion.
- **German Market Supply Issues:** The company noted some supply disruptions in its German business (revenue declined ~6% in constant currency), which remains a minor drag on overall international performance.

## 4) Latest Analyst Targets (as of Feb 14, 2026)

# Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

The following table summarizes the latest available price targets from major brokerages. *Note: Some targets were set prior to the Feb 13 earnings and may be revised upwards in the coming days given the strong Q3 beat.*

Brokerage / Firm	Rating	Target Price (INR )	Date / Status
Jefferies	Buy	4,600	Jan 07, 2026
Nuvama	Buy	4,180	Nov 25, 2025
JM Financial	Buy	4,255	Nov 09, 2025
Axis Capital	Buy	4,040	Nov 2025
BofA Securities	Buy	4,000	Nov 10, 2025
Nomura	Neutral	3,621	Oct 28, 2025
ICICI Securities	Hold	3,530	Nov 09, 2025
Consensus Mean	Buy	~4,080	Feb 14, 2026

**Summary View:** The stock is currently trading near its all-time high (~INR 4,100 levels). While the Q3 results were strong, the current price is close to the average consensus target, suggesting that while the fundamental story is excellent, the valuation is demanding. The **Jefferies** target of INR 4,600 implies the highest potential upside (~12%) from current levels.


# **Stock Detailed Analysis Report**

**TORNTPHARM.NS**

Current Price: ₹4078.00

Generated: 2026-02-14 10:11

# TORNTPHARM.NS - 3 Year Daily Price Chart



## Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	7.15%	10.36%
Net Income	Yes	No	15.39%	34.98%
ROE	Yes	No	4.22%	24.48%
EPS	Yes	No	15.39%	34.98%

## Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	3.77%	3.55%
Net Income	Yes	7.85%	6.98%
ROE	Yes	6.57%	7.65%
EPS	Yes	7.78%	6.01%

# TORNTPHARM.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	54.8/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.035 [Leader]</b>
3M RS:	<b>1.083 [Leader]</b>
6M RS:	<b>1.084 [Leader]</b>
1Y RS:	<b>1.266 [Strong]</b>
:	




## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	

## SIGNAL CRITERIA::

✗ Emerging RS:	<b>Not accelerating</b>
✗ Medium-term Lagging:	<b>Not lagging</b>
✗ Performance Improving:	<b>Not improving</b>


**Relative Strength Analysis: TORNTPHARM.NS vs ^CNXPHARMA**  
**Classification: Weakening Leader**  
**Price Performance Comparison (Normalized)**



## **TORNTPHARM.NS - EMA Crossover Summary**

<b>EMA 20:</b>	4004.35
<b>EMA 50:</b>	3923.19
<b>EMA 200:</b>	3641.30
<b>Trend Status:</b>	<b>Strong Uptrend</b>
<b>Golden Cross Date:</b>	2022-02-16 00:00:00+05:30
<b>Golden Cross Price:</b>	1259.81

# TORNTPHARM.NS EMA Crossover Analysis



## **TORNTPHARM.NS - Bollinger Bands Summary**

<b>Current Price:</b>	4078.00
<b>Upper Band:</b>	4108.53
<b>Middle Band (SMA 20):</b>	4006.18
<b>Lower Band:</b>	3903.82
<b>%B:</b>	0.8509
<b>Band Width:</b>	0.0511
<b>Status:</b>	Upper Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Buy Signal at 2026-01-30 00:00:00+05:30</b>

# TORNTPHARM.NS Bollinger Bands (20, 2) Analysis




## **TORNTPHARM.NS - Supertrend Summary**

**Status:** UPTREND (Buy)

**Supertrend Value:** 3839.61

**Signal Identified On:** 2025-11-10

### Supertrend Analysis for TORNTPHARM.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## **TORNTPHARM.NS - MACD Summary**

<b>MACD Line:</b>	38.71
<b>Signal Line:</b>	34.75
<b>Histogram:</b>	3.96
<b>Trend:</b>	<b>Bullish</b>
<b>Momentum:</b>	<b>Strengthening</b>
<b>Signal:</b>	None

### TORNTPHARM.NS Price




### TORNTPHARM.NS MACD (12, 26, 9)



## **TORNTPHARM.NS - Volatility Squeeze Summary**

<b>BB Width:</b>	0.0511
<b>ATR:</b>	101.6143
<b>Total Signals:</b>	26
<b>Signal 1:</b>	BB Squeeze + ATR Contraction at 2025-12-30 00:00:00+05:30 (Price: 3885.30)
<b>Signal 2:</b>	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Price: 3869.80)
<b>Signal 3:</b>	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Price: 3885.30)
<b>Signal 4:</b>	BB Squeeze at 2026-01-02 00:00:00+05:30 (Price: 3885.30)
<b>Signal 5:</b>	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 3869.80)


## TORNTPHARM.NS - Volatility Squeeze Analysis



## **TORNTPHARM.NS - RSI-Volume Summary**

<b>Current RSI:</b>	59.33
<b>Current Volume:</b>	518965
<b>Volume MA 20:</b>	307091
<b>Bullish Divergences:</b>	1
<b>Bearish Divergences:</b>	1
<b>Bullish Div 1:</b>	Date: 2024-11-19 00:00:00+05:30, Price: 3065.07
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00+05:30, Price: 3328.68

# TORNTPHARM.NS RSI-Volume Divergence Analysis



# **TORNTPHARM.NS - Volume Analysis**

## **== VOLUME ANALYSIS ==:**

**Status:** 33 Signals Detected

:

**2025-12-11 [+]:** Buying Exhaustion (Bearish Div)



**2026-01-13 [-]:** Distribution Day

**2026-01-28 [-]:** Distribution Day

**2026-01-30 [-]:** Climax Volume (Churning)

**2026-02-04 [-]:** Distribution Day

## TORNTPHARM.NS - Volume Analysis



# **TORNTPHARM.NS - Candlestick Classification Summary**

## **== CANDLESTICK CLASSIFICATION ==:**

**Latest Classification:** Seller Control

**Recent Trend Score (10-day avg):** 0.20

:

### **Distribution:**

**No Control:** 123


**Buyer Control:** 61

**Seller Control:** 40

**Buyer Strong Control:** 3

**Seller Strong Control:** 1

# TORNTPHARM.NS - Candlestick Classification



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	3725.73	4078.0	2025-07-14
1 Day	UPTREND (Buy)	3839.61	4078.0	2025-11-10
15 Min	DOWNTREND (Sell)	4119.72	4066.7	2026-02-13

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Strengthening	No Signal
1 Day	Bullish	Strengthening	No Signal
15 Min	Bearish	Strengthening	No Signal

# TORNTPHARM.NS - 1 Week (Candlestick + EMAs)



# TORNTPHARM.NS - 1 Day (Candlestick + EMAs)



# TORNTPHARM.NS - 15 Min (Candlestick + EMAs)





## Trendlyne Snapshot - TORNTPHARM\_forecaster

Markets STARFOLIO Alerts F&O MF Reports Screeners [Subscribe](#) Superstars Portfolio Watchlist Insider Trades Results Data Downloader More [A](#)

Search Stock, IPO, MF [India](#)

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / [TORRENT PHARMACEUTICALS LTD.](#)

### Torrent Pharmaceuticals Ltd. [①](#)

NSE:TORNTPHARM | BSE: 500420  
Expensive Star [①](#) In 1 Starfolio Basket

Download real time STOCK REPORT

**4078.00** 0.80 (0.02%) [↑ New 52W High today](#)

**528.0K** NSE+BSE Volume  
NSE 13 Feb, 2026 3:31 PM (IST)

Watchlist Portfolio Alert My Notes TRADE STOCK

Rapid Results Q3FY26 Quarterly Result Announced for Torrent Pharmaceuticals Ltd. See details


Overview FORECASTER STOCK REPORT Buy Sell Zone F&O Financials News Reports Technicals Shareholding Deals Corporate Actions Alerts About

### Torrent Pharma - TORNTPHARM - stock price prediction, stock forecast, target price, analyst ratings from 27 analysts

Torrent Pharma has a share price target of Rs 4080, revenue growth forecast of 13.3%, and profit growth estimate of 26.5% for FY26, based on top 27 analyst calls.

### Torrent Pharma FORECASTER - Analyst Estimates [①](#)

[FORECASTER DASHBOARD →](#)



BUY

CONSENSUS RECOMMENDATION

27 ANALYST Recommendations

Strong Buy	Buy	Hold	Sell	Date
12	7	6	1	Sep '25
12	6	7	1	Oct '25
14	6	6	1	Nov '25
14	6	6	1	Dec '25
14	6	6	1	Jan '26
14	6	6	1	Feb '26

● Strong Buy ● Buy ● Hold ● Sell